Earnings Call Summary | BioCardia(BCDA.US) Q4 2023 Earnings Conference
Earnings Call Summary | BioCardia(BCDA.US) Q4 2023 Earnings Conference
The following is a summary of the BioCardia, Inc. (BCDA) Q4 2023 Earnings Call Transcript:
以下是BioCardia, Inc.（BCDA）2023年第四季度财报电话会议记录摘要：
Financial Performance:
财务业绩：
BioCardia's revenues fell to $0.5 million in 2023 from $1.4 million in the previous year, primarily due to the timing of revenue recognition from its collaboration partners.
Expenses decreased by 9% with significant savings in research and development expenditure, which dropped to $7.7 million in 2023 from $8.8 million in 2022.
2023 ended with a net loss of $11.6 million, slightly less than the $11.9 million net loss in 2022.
BioCardia had $1.1 million in cash by the end of 2023, sufficient to sustain operations until Q2 2024.
BioCardia的收入从去年的140万美元降至2023年的50万美元，这主要是由于其合作伙伴确认收入的时机所致。
支出下降了9％，研发支出大幅减少，从2022年的880万美元降至2023年的770万美元。
2023年结束时净亏损1160万美元，略低于2022年的1190万美元净亏损。
到2023年底，BioCardia拥有110万澳元的现金，足以维持运营至2024年第二季度。
Business Progress:
业务进展：
BioCardia displayed promising development of lead CardiAMP autologous cell therapy for treating ischemic heart failure.
Despite missing the primary pre-specified endpoint in the Cardiac Heart Failure clinical trial, the results supported the continuation of the program.
BioCardia is also advancing with the CardiAMP Heart Failure II study, the CardiAMP cell therapy trial for chronic myocardial ischemia (BCDA-02), and a partnership with StemCardia.
The company has shifted its Helix Biotherapeutic Delivery Partnering Business to focus on longer-term partnerships, planning to have two additional partners in 2024.
BioCardia aims to broaden the FDA-cleared Helix system and Morph DNA platform to cover cardiac and peripheral vascular disease indications.
It has recorded an encouraging reduction in cardiac arrhythmias in the BCDA-01 trial's interim data and plans to pre-specify this as a secondary endpoint in future trials.
Expansion in the CardiAMP Heart Failure II confirmatory study and consultations with Japan's PMDA remain high on the agenda.
With five cardiac biotherapeutic programs in development, BioCardia is on track to continue its mission of addressing heart disease.
BioCardia展示了治疗缺血性心力衰竭的先导CardiAMP自体细胞疗法的发展前景。
尽管在心脏心力衰竭临床试验中没有达到预先规定的主要终点，但结果支持了该计划的延续。
BioCardia还在推进Cardiamp心力衰竭II研究、针对慢性心肌缺血的Cardiamp细胞疗法试验（BCDA-02）以及与Stemcardia的合作。
该公司已将其Helix生物治疗交付合作业务转向长期合作伙伴关系，并计划在2024年再增加两个合作伙伴。
BioCardia旨在扩大经美国食品药品管理局批准的Helix系统和Morph DNA平台，以涵盖心脏和外周血管疾病的适应症。
它在 BCDA-01 试验的中期数据中记录了令人鼓舞的心律失常的减少，并计划在未来的试验中将其预先指定为次要终点。
扩大Cardiamp心力衰竭II确认性研究以及与日本PMDA的磋商仍然是议程的重中之重。
随着五项心脏生物治疗项目正在开发中，BioCardia有望继续其解决心脏病的使命。
More details: BioCardia IR
更多详情： BioCardia IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多详情，请访问投资者关系网站。本文仅供投资者参考，不构成任何投资建议。
译文内容由第三方软件翻译。